Perrigo (NYSE:PRGO) Issues FY 2026 Earnings Guidance

Perrigo (NYSE:PRGO) updated its FY 2026 earnings guidance on Wednesday morning. The company provided EPS guidance of 2.250-2.550 for the period, compared to the consensus EPS estimate of 2.110. The company issued revenue guidance of $4.0 billion-$4.2 billion, compared to the consensus revenue estimate of $4.1 billion.

Perrigo Stock Up 0.7%

NYSE:PRGO opened at $10.76 on Wednesday. Perrigo has a 1 year low of $9.23 and a 1 year high of $26.99. The stock has a 50-day moving average price of $10.52 and a two-hundred day moving average price of $11.56. The stock has a market cap of $1.49 billion, a price-to-earnings ratio of -0.82, a PEG ratio of 1.28 and a beta of 0.51. The company has a current ratio of 2.72, a quick ratio of 1.59 and a debt-to-equity ratio of 1.45.

Perrigo (NYSE:PRGO) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.50 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $0.16. Perrigo had a positive return on equity of 9.96% and a negative net margin of 43.50%.The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. As a group, equities analysts expect that Perrigo will post 2.09 earnings per share for the current year.

Perrigo Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Friday, August 28th will be issued a dividend of $0.29 per share. This represents a $1.16 annualized dividend and a yield of 10.8%. The ex-dividend date is Friday, August 28th. Perrigo’s dividend payout ratio (DPR) is -8.85%.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on PRGO shares. Weiss Ratings raised shares of Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 21st. Zacks Research upgraded shares of Perrigo from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. One research analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $19.33.

Hedge Funds Weigh In On Perrigo

A number of large investors have recently bought and sold shares of the company. Corient Private Wealth LLC bought a new position in shares of Perrigo during the 4th quarter worth approximately $283,000. T. Rowe Price Investment Management Inc. grew its position in Perrigo by 35.5% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,386,111 shares of the company’s stock valued at $19,295,000 after purchasing an additional 363,501 shares in the last quarter. Invesco Ltd. grew its position in Perrigo by 134.2% in the fourth quarter. Invesco Ltd. now owns 4,542,415 shares of the company’s stock valued at $63,230,000 after purchasing an additional 2,602,724 shares in the last quarter. Vident Advisory LLC increased its stake in Perrigo by 7.0% in the 4th quarter. Vident Advisory LLC now owns 51,098 shares of the company’s stock valued at $711,000 after buying an additional 3,350 shares during the last quarter. Finally, First Citizens Bank & Trust Co. lifted its position in Perrigo by 126.3% during the 4th quarter. First Citizens Bank & Trust Co. now owns 39,207 shares of the company’s stock worth $546,000 after buying an additional 21,884 shares in the last quarter. Institutional investors and hedge funds own 95.91% of the company’s stock.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.